Last updated on November 2018

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

Clinical Study Identifier: NCT03155997

Contact Investigators or Research Sites near you

Start Over

Marie Ange Mouret-Reynier

Centre Jean Perrin
Clermont Ferrand BP 392, France
  Connect »